Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

Jinhai Medical Technology Limited
今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER THE GENERAL MANDATE

Reference is made to the announcement of Jinhai Medical Technology Limited (the "**Company**") dated 11 July 2025 in relation to the subscription of new shares under the general mandate (the "**Announcement**"). Unless the context requires otherwise, terms defined in the Announcement shall have the same meaning when used in this announcement.

COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the conditions precedent for the Subscriptions have been fulfilled and Completion took place on 15 August 2025. A total of 120,000,000 Subscription Shares have been successfully issued to the nominees of the Subscribers at the Subscription Price of HK$1.35 per Share. The Subscription Shares represent (i) 2.32% of the existing issued share capital of the Company immediately before Completion; and (ii) approximately 2.27% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares.

The aggregate gross proceeds from the Subscription amounted to approximately HK$162.0 million. The aggregate net proceeds from the Subscription, after deduction of relevant costs and expenses, amounted to approximately HK$161.0 million. The Group intends to use the proceeds from the Subscriptions for (i) financing potential mergers and acquisitions of healthcare related projects and/or companies and investment in healthcare related industries; (ii) research and development expenses; and (iii) general working capital.

EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below are the shareholding structures of the Company (i) immediately before Completion; and (ii) immediately upon Completion respectively:

	Immediately before Completion		**Immediately after Completion**	
	Number of Shares	*Approximate %*	*Number of Shares*	*Approximate %*
Full Fortune International Co., Ltd. *(Note 1)*	2,530,000,000	48.94	2,530,000,000	47.82
Subscriber A	–	–	40,000,000	0.76
Subscriber B	–	–	40,000,000	0.76
Subscriber C	–	–	40,000,000	0.76
Other public Shareholders	2,640,000,000	51.06	2,640,000,000	49.90
Total	**5,170,000,000**	**100.00**	**5,290,000,000**	**100.00**

Note:

(1) The entire issued share capital of Full Fortune International Co., Ltd. is beneficially owned by Mr. Chen Guobao, the Chairman and an executive Director.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board

Hong Kong, 15 August 2025

As at the date of this announcement, the Board comprises eight Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping; two are non-executive Directors, namely Mr. Jiang Jiangyu and Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.